2.The prospect and challenge of liquid biopsy in the diagnosis and treatment of chest malignancy.
Li Fang MA ; Bing Jie ZENG ; Xian Zhao WANG ; Xiao ZHANG ; Jia Yi WANG
Chinese Journal of Preventive Medicine 2023;57(7):968-975
In recent years, the incidence of chest malignant tumors in China has increased year by year, which has seriously threatened the health problems of people. Among them, early screening and intervention of patients with chest malignancies is the key to cancer prevention. Early detection, early diagnosis, and early treatment as the "three early prevention" of clinical practice are conducive to improve the survival rate of tumor patients. As a non-invasive and real-time reflection of tumor status, liquid biopsy has gradually received attention in clinical diagnosis and treatment. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes as liquid biopsy "Three carriages" are not only widely used in the diagnosis, monitoring and prognostic evaluation of chest malignancies, but also face many unknown challenges. In this article, the application of liquid biopsy in chest malignancies in recent years is elaborated in detail, which provides a reference for the formulation of clinical tumor prevention and diagnosis and treatment strategies.
Humans
;
Circulating Tumor DNA/genetics*
;
Liquid Biopsy/methods*
;
Neoplastic Cells, Circulating/pathology*
;
China
;
Biomarkers, Tumor
4.Chinese expert consensus on the application of circulating tumor cell detection in the diagnosis and treatment of gastrointestinal neoplasms (2023 edition).
Chinese Journal of Gastrointestinal Surgery 2023;26(11):1001-1007
Circulating tumor cell (CTC), as a novel tumor marker, has the characteristics of non-invasive, dynamic monitoring and high accuracy, and provides precise molecular characteristics of tumors and helps understand the changes in tumor development. Therefore, CTC has important clinical value in the dynamic monitoring of tumor progression. In order to standardize and guide the application of CTC detection in the diagnosis and treatment of gastrointestinal neoplasms, Gastric Cancer Group of Oncology Branch of Chinese Medical Association, Colorectal Cancer Professional Committee of Chinese Medical Doctor Association, Colorectal Cancer Professional Committee of Chinese Anti-Cancer Association, Gastric Cancer Professional Committee of Chinese Anti-Cancer Association, Digestive Tract Polyp and Precancerous Lesion Professional Committee of Chinese Anti-Cancer Association, jointly convened some domestic experts to discuss and formulate the Chinese expert consensus on the application of circulating tumor cell detection in the diagnosis and treatment of gastrointestinal neoplasms (2023 edition). The consensus provides opinions on the detection technology and clinical application of CTC detection in the diagnosis and treatment of gastrointestinal neoplasms, including the prediction of tumor prognosis, the monitoring of tumor recurrence and metastasis, the evaluation of treatment response, and the additional diagnostic value, providing guidance for clinical application.
Humans
;
Stomach Neoplasms/therapy*
;
Neoplastic Cells, Circulating/pathology*
;
Consensus
;
Neoplasm Recurrence, Local
;
Colorectal Neoplasms/therapy*
5.Correlation between increased circulating endothelial progenitor cells and stage of non-Hodgkin lymphoma.
Dan-dan YU ; Hong-li LIU ; Yun-lin BAI ; Bian WU ; Wei-hong CHEN ; Jing-hua REN ; Tao ZHANG ; Kun-yu YANG ; Gang WU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2013;33(2):284-287
This study aims to examine the levels of circulating endothelial progenitor cells (cEPCs) in the peripheral blood of patients with non-Hodgkin lymphoma (NHL) and their correlation with the tumor stage. Forty-one patients with biopsy-proven NHL and 16 healthy individuals were recruited. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation, and cEPCs were characterized by triple staining using antibodies against CD133, CD34 and vascular endothelial growth factor receptor-2 (VEGFR-2, CD309) and quantified by flow cytometry. In NHL patients, the number of cEPCs was significantly greater than in control group (P=0.000). The cEPCs counts in patients with NHL of stage III-IV were significantly greater than in stage I-II (P=0.010). FACS analysis revealed that the number of cEPCs in NHL patients had no correlation with the gender (P=0.401) or the pathological category (P=0.852). It was suggested that the over-expression of cEPCs in NHL patients may serve as a novel biomarker for disease progression in NHL.
Blood Cell Count
;
Cells, Cultured
;
Endothelial Cells
;
pathology
;
Female
;
Humans
;
Lymphoma, Non-Hodgkin
;
blood
;
pathology
;
Male
;
Neoplastic Cells, Circulating
;
pathology
;
Statistics as Topic
;
Stem Cells
;
pathology
6.Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer.
Theodore GOURDIN ; Guru SONPAVDE
Asian Journal of Andrology 2018;20(3):230-237
Prostate cancer is characterized by bone metastases and difficulty of objectively measuring disease burden. In this context, cell-free circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) quantitation and genomic profiling afford the ability to noninvasively and serially monitor the tumor. Recent data suggest that ctDNA and CTC quantitation are prognostic for survival. Indeed, CTC enumeration using the CellSearch® platform is validated as a prognostic factor and warrants consideration as a stratification factor in randomized trials. Changes in quantities of CTCs using CellSearch also are prognostic and may be employed to detect a signal of activity of new agents. Molecular profiling of both CTCs and ctDNA for androgen receptor (AR) variants has been associated with outcomes in the setting of novel androgen inhibitors. Serial profiling to detect the evolution of new alterations may inform drug development and help develop precision medicine. The costs of these assays and the small quantities in which they are detectable in blood are a limitation, and novel platforms are required to address this challenge. The presence of multiple platforms to assay CTCs and ctDNA also warrants the consideration of a mechanism to allow comparison of data across platforms. Further validation and the continued development and standardization of these promising modalities will facilitate their adoption in the clinic.
Biomarkers, Tumor/blood*
;
DNA, Neoplasm/blood*
;
Humans
;
Male
;
Neoplastic Cells, Circulating/immunology*
;
Prognosis
;
Prostatic Neoplasms/pathology*
;
Transcriptome
7.Surgical treatment of hepatocellular carcinoma with tumor thrombus in the inferior vena cava.
Yi WANG ; Han CHEN ; Meng-chao WU ; Yan-fu SUN ; Chuan LIN ; Xiao-qing JIANG ; Gong-tian WEI
Chinese Journal of Surgery 2003;41(3):165-168
OBJECTIVETo clarify the proper surgical procedure of treating hepatocellular carcinoma (HCC) with a tumor thrombus in the inferior vena cava (IVC).
METHODSFour patients with HCC with a tumor thrombus in the IVC underwent hepatectomy and thrombectomy. Following hepatectomy, tumor thrombus was removed by incising the wall of the IVC in 3 patients and from the hepatic vein in one patient. The 3 patients underwent thrombectomy under either hepatic vascular exclusion (HVE) or Satinsky's vascular clamping.
RESULTSAll the operations were successful without operative death and major complications. The postoperative course was uneventful in 3 patients and pleural effusion occurred in one patient who needed thoracentesis. Follow-up showed 3 patients died after 30, 10 and 14 months, respectively, and one patient is alive for 7 months.
CONCLUSIONSHCC with tumor thrombus in the IVC is operable and the proper procedure is hepatectomy plus thrombectomy.
Carcinoma, Hepatocellular ; complications ; surgery ; Humans ; Liver Neoplasms ; complications ; surgery ; Male ; Middle Aged ; Neoplastic Cells, Circulating ; Vena Cava, Inferior ; pathology
8.The study of associations between circulating tumor cells and clinicopathologic characteristics in axillary lymph node positive primary breast cancer.
Yijun ZHOU ; Tao OUYANG ; Tianfeng WANG ; Yuntao XIE ; Zhaoqing FAN ; Tie FAN ; Jinfeng LI
Chinese Journal of Surgery 2014;52(6):420-424
OBJECTIVETo investigate the correlations between circulating tumor cell (CTC) and clinicopathologic characteristics of tumors obtained by core needle biopsy in axillary lymph node positive primary breast cancer patients.
METHODSThe peripheral venous blood samples were collected from 126 patients with axillary lymph node positive primary breast cancer and were detected to found CTCs using the CellSearch automatic detection system. The associations between CTCs and clinicopathologic characteristics of tumors were analyzed in axillary lymph node positive primary breast cancer patients. All patients were female, age ranging from 27 to 65 years (median, 49 years).
RESULTSOne or more CTCs were detected from the peripheral blood in 25.4% (32/126) patients. The positive rate of CTCs was 36.2% (17/47) in the human epidermal growth factor receptor 2 (HER-2) (+) patients, 19.0% (15/79) in the HER-2 (-) patients. In univariate analysis, there were significant differences about the positive rate of CTCs between the two groups (χ² = 4.592, P < 0.05). In multivariate analysis, the risk of circulating tumor cells positive in HER-2 (+) patients was 2.712 times higher than in HER-2 (-) patients (OR = 2.712, 95% CI: 1.117-6.584, P = 0.027), whereas the positive rate of CTCs in axillary lymph node positive primary breast cancer patients showed no significant differences among the different subgroups with regards to age, menopausal status, the T staging of the tumor, histological type, histological grade, hormone receptor status and Ki-67 expression level (P > 0.05).
CONCLUSIONSThere are significant correlations between the presence of CTCs and the HER-2 status of the tumor in axillary lymph node positive primary breast cancer patients. No significant correlations are found between the presence of CTCs and the age, menopausal status, T staging of the tumor, histological type, histological grade, hormone receptor status and Ki-67 expression level.
Adult ; Aged ; Axilla ; pathology ; Breast Neoplasms ; pathology ; Female ; Humans ; Lymph Nodes ; pathology ; Lymphatic Metastasis ; pathology ; Middle Aged ; Neoplastic Cells, Circulating ; pathology ; Receptor, ErbB-2 ; metabolism
9.Renal collecting duct carcinoma associated with tumor embolus in the inferior vena cava.
Ling-Ling GUO ; Mei-Qing WANG ; Yi-Ran CAI ; Yan WANG
Chinese Journal of Pathology 2005;34(2):123-124
Carcinoma, Renal Cell
;
immunology
;
pathology
;
surgery
;
Humans
;
Keratin-19
;
metabolism
;
Kidney Neoplasms
;
immunology
;
pathology
;
surgery
;
Male
;
Middle Aged
;
Neoplastic Cells, Circulating
;
pathology
;
Nephrectomy
;
Vena Cava, Inferior
;
pathology
;
surgery
10.Clinical Features of Neuroendocrine Tumor of the Pancreas: Single Center Study.
Tae Wook KANG ; Kyu Taek LEE ; Min Kyu RYU ; Won MOON ; Sang Soo LEE ; Sun Young LEE ; Ji Young HWANG ; Jong Kyun LEE ; Jin Seok HEO ; Seong Ho CHOI ; Sang Heum KIM ; Seung Woon PAIK ; Jong Chul RHEE
The Korean Journal of Gastroenterology 2006;48(2):112-118
BACKGROUND/AIMS: Pancreatic neuroendocrine tumors (PNET) are rare and manifest as functioning tumor (FT) or non-functioning tumor (NFT). Although malignant changes are observed in some cases, its prognosis is better than pancreatic cancer. We evaluated clinicoradiologic features and prognosis of FT and NFT. In addition, we tried to find the predictive factors for the recurrence of NFT after resection. METHODS: Between October 1994 and June 2004, we retrospectively evaluated the clinicopathologic features and prognosis of 12 cases of FT and 31 cases of NFT diagnosed by surgical pathology at single medical center in Korea. RESULTS: PNET included 6 insulinomas, 4 gastrinomas, 1 glucagonoma, 1 somatostatinoma and 31 NFT. The major clinical manifestations were neuroglycopenic symptoms (100%) in insulinoma, abdominal ulcer symptoms (75%) in gastrinoma, dermatitis (100%) in glucagonoma, steatorrhea (100%) in somatostatinoma, and abdominal discomfort or pain (45%) in NFT. NFT was located more proximally when compared to FT (p=0.023). NFT showed more malignant (64.5%) behavior compared to FT (41.7%) despite the lack of statistical significance. Curative resections were done without postoperative death in 38 cases. Six cases of NFT (21.4%) and 1 case of FT (10%) recurred with an average of 26.5 months. In the recurrent NFT, the findings of diabetes mellitus (p=0.010), abnormal pancreatic duct (p=0.026), Whipple's operation (p=0.013) and tumor emboli (p=0.03) were more common than in non-recurrent NFT. CONCLUSIONS: FT and NFT showed different clinicoradiologic features. In addition, NFT should be monitored more carefully because of frequent recurrence.
Adult
;
Diabetes Mellitus/pathology
;
Female
;
Humans
;
Male
;
Middle Aged
;
Neoplastic Cells, Circulating/pathology
;
Neuroendocrine Tumors/complications/*diagnosis
;
Pancreatic Ducts/abnormalities/pathology
;
Pancreatic Neoplasms/complications/*diagnosis
;
Whipple Disease/complications